In 2016 was created Sigma Square Capital, which is appeared as VC. The fund was located in Asia if to be more exact in China. The main office of represented VC is situated in the Beijing.
Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. This Sigma Square Capital works on 11 percentage points less the average amount of lead investments comparing to the other organizations.
Besides them, we counted 3 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Sigma Square Capital, startups are often financed by ZhenFund, Yueyin Venture Capital, Pan-Lin Asset Management. The meaningful sponsors for the fund in investment in the same round are Lightspeed China Partners, China Growth Capital, Zhonglu Capital. In the next rounds fund is usually obtained by Xiaopeng He, Qiming Venture Partners, OceanIQ Capital.
The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Novogene, WeRide.ai, Liking Fit. Among the most popular fund investment industries, there are Advertising, Fitness. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
Funds with similar focus
|Actinic Ventures||New York, New York, United States|
|Banque des Territoires||-|
|Club Network Investments||Stockholm, Stockholm County, Sweden|
|Coditel S.A||Canton Luxembourg, Luxembourg, Strassen|
|GVA Vestor.in||California, San Francisco, United States|
|Humus Capital||Argentina, Buenos Aires, Distrito Federal|
|IncSyn Business Incubation Ltd.||-|
|Indies Capital Partners||Central, Central Region, Singapore|
|Mediphase Venture Partners||Massachusetts, Newton, United States|
|Mobvista||China, Japan, Kagoshima Prefecture|
|Modalku||East Java, Indonesia, Kebon|
|SG INCUBATE||Fukuoka, Fukuoka Prefecture, Japan|
|Shanghai Minority Asset Management||China, Shanghai|
|TechSpace||Aliso Viejo, California, United States|
|Tong Yang Venture Capital||Seoul, Seoul-t'ukpyolsi, South Korea|
|Triage Ventures||California, San Francisco, United States|
|University of Cape Town||Gauteng, NA - South Africa, South Africa|
|$93M||22 Feb 2021||Woburn, Massachusetts, United States|
|$15M||13 Mar 2020||Qingdao, Shandong, China|
|04 Mar 2020||China, Wuwei|
|$15M||17 Jul 2019||China, Wuwei, China|
|$15M||18 Feb 2019||Dongcheng District, Beijing, China|
|$6M||18 Dec 2018||China, Shanghai|
|27 Jul 2018||Futian District, Guangdong Province, China|
|$54M||15 Jan 2018||Shanghai, China|
No Panda Culture (Bukongwenhua)
|$9M||16 Sep 2017||Dongcheng District, Beijing, China|
– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.